stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) EBITDA
ADMA Biologics Inc's EBITDA for fiscal 2025 was $200.1M, up 35.4% from $147.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was $232.8M. Over the past ten years it has ranged from −$59.3M (fiscal 2020) to $200.1M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 5 consecutive fiscal years. ADMA Biologics Inc ranks 19th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $200.1M | 35.36% |
| FY2024 | $147.8M | 356.07% |
| FY2023 | $32.4M | — |
| FY2022 | −$30.0M | — |
| FY2021 | −$51.1M | — |
| FY2020 | −$59.3M | — |
| FY2019 | −$37.1M | — |
| FY2018 | −$55.9M | — |
| FY2017 | −$36.0M | — |
| FY2016 | −$16.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $54.4M | (9.76%) |
| Mar 2026 | $60.3M | (7.22%) |
| Dec 2025 | $65.0M | 22.17% |
| Sep 2025 | $53.2M | 18.20% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement